| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/01/2023 | 15.7% | Morgan Stanley | $40 → $36 | Maintains | Equal-Weight |
| 08/23/2023 | 38.2% | Guggenheim | $41 → $43 | Maintains | Buy |
| 08/22/2023 | 38.2% | Guggenheim | $41 → $43 | Maintains | Buy |
| 08/22/2023 | 31.77% | B of A Securities | → $41 | Initiates Coverage On | → Buy |
| 08/11/2023 | 22.13% | JP Morgan | → $38 | Initiates Coverage On | → Neutral |
| 06/01/2023 | 38.2% | Macquarie | → $43 | Initiates Coverage On | → Outperform |
| 05/26/2023 | 28.56% | Morgan Stanley | → $40 | Initiates Coverage On | → Equal-Weight |
| 05/26/2023 | 28.56% | Goldman Sachs | → $40 | Initiates Coverage On | → Neutral |
| 05/17/2023 | 18.91% | Guggenheim | → $37 | Initiates Coverage On | → Buy |
| 04/24/2023 | 15.7% | Seaport Global | → $36 | Initiates Coverage On | → Buy |
| 02/10/2023 | 124.97% | Morgan Stanley | $50 → $70 | Maintains | Equal-Weight |
| 12/15/2022 | 60.69% | Morgan Stanley | → $50 | Upgrades | Underweight → Equal-Weight |
| 11/15/2022 | 57.48% | Jefferies | $100 → $49 | Downgrades | Buy → Hold |
| 11/11/2022 | 60.69% | Morgan Stanley | $63 → $50 | Maintains | Underweight |
| 08/23/2022 | 173.18% | Guggenheim | $96 → $85 | Maintains | Buy |
| 06/15/2022 | 102.47% | Morgan Stanley | $65 → $63 | Maintains | Underweight |
| 06/02/2022 | 134.61% | Wolfe Research | $88 → $73 | Maintains | Peer Perform |
| 02/10/2022 | 205.32% | Oppenheimer | $115 → $95 | Maintains | Outperform |
| 11/01/2021 | 153.9% | JP Morgan | $105 → $79 | Maintains | Neutral |
| 01/19/2021 | 173.18% | Morgan Stanley | $80 → $85 | Maintains | Equal-Weight |
| 10/06/2020 | 221.39% | JP Morgan | → $100 | Initiates Coverage On | → Overweight |
| 07/30/2020 | 157.11% | Morgan Stanley | → $80 | Initiates Coverage On | → Equal-Weight |
| 07/13/2020 | 134.61% | Imperial Capital | → $73 | Initiates Coverage On | → In-Line |
| 06/29/2020 | 221.39% | Jefferies | → $100 | Initiates Coverage On | → Buy |
| 06/17/2020 | 272.81% | Guggenheim | → $116 | Initiates Coverage On | → Buy |
What is the target price for Madison Square Garden (MSGE)?
The latest price target for Madison Square Garden (NYSE: MSGE) was reported by Morgan Stanley on September 1, 2023. The analyst firm set a price target for $36.00 expecting MSGE to rise to within 12 months (a possible 15.70% upside). 14 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Madison Square Garden (MSGE)?
The latest analyst rating for Madison Square Garden (NYSE: MSGE) was provided by Morgan Stanley, and Madison Square Garden maintained their equal-weight rating.
When is the next analyst rating going to be posted or updated for Madison Square Garden (MSGE)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Madison Square Garden, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Madison Square Garden was filed on September 1, 2023 so you should expect the next rating to be made available sometime around September 1, 2024.
Is the Analyst Rating Madison Square Garden (MSGE) correct?
While ratings are subjective and will change, the latest Madison Square Garden (MSGE) rating was a maintained with a price target of $40.00 to $36.00. The current price Madison Square Garden (MSGE) is trading at is $31.12, which is out of the analyst's predicted range.